Unloxcyt cosibelimab 300 mg concentrate for solution for infusion Sun Pharma ANZ Pty Ltd
Product name
Unloxcyt cosibelimab 300 mg concentrate for solution for infusion
Sponsor
Accepted date
Jun-2026
Active ingredients
cosibelimab
Summary of proposed indication
UNLOXCYT (cosibelimab) is proposed for the treatment of adults with cutaneous squamous cell carcinoma, a type of skin cancer, that has spread to other parts of the body or has grown locally. It is intended for use when the cancer cannot be treated with surgery or radiation therapy.
Application type
A (new medicine)
Publication date
Jun-2026